Lorlatinib

Red

Brand Name(s):Lorviqua

Indication:anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

Rationale:1,2

Considered:Sep-19

Review Date:Aug-25

Comments:
Lorlatinib as monotherapy is licensed for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer whose disease has progressed after alectinib or ceritinib; or crizotinib & at least one other ALK tyrosine kinase inhibitor. NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020)